A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia

European Neuropsychopharmacology

Volumn 24, Issue 3, 2014, Pages 425-436

  Gil Ad, Irit ^a   Portnoy, Moshe ^a   Tarasenko, Igor ^a   Bidder, Miri ^a   Kramer, Maria ^a   Taler, Michal ^a   Weizman, Abraham ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Antipsychotic; Glutamate; N methyl d aspartate receptor (NMDA R); Negative symptoms; Positive symptoms; Schizophrenia

Indexed keywords

ALANINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; DIZOCILPINE MALEATE; NEUROLEPTIC AGENT; OLANZAPINE; PGW5 COMPOUND; PHENCYCLIDINE;

ANALOGS AND DERIVATIVES; ANIMAL; ANXIETY; BAGG ALBINO MOUSE; BRAIN; C57BL MOUSE; DEPRESSION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; DRUG THERAPY; EXPLORATORY BEHAVIOR; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

ALANINE; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOTOR ACTIVITY; PHENCYCLIDINE; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 84894382526     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.11.009     Document Type: Article

References (51)

1. Abidi S., Bhaskara S.M. From chlorpromazine to clozapine-antipsychotic adverse effects and the clinician's dilemma. Can. J. Psychiatry 2003, 48:749-755.
2. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
3. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 1998, 18:8394-8401.
4. Balaratnasingam S., Janca A. Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol. Ther. 2012, 134:116-124.
5. Barzilay R., Ben-Zur T., Sadan O., Bren Z., Taler M., Lev N., Tarasenko I., Uzan R., Gil-Ad I., Melamed E., Weizman A., Offen D. Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Transl. Psychiatry 2011, 1:e61.
6. Barzilay R., Ganz J., Sadan O., Ben-Zur T., Bren Z., Hinden N., Taler M., Lev N., Gil-Ad I., Weizman A., Offen D. Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro. Eur. Neuropsychopharmacol 2012.
7. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
8. Brigman J.L., Ihne J., Saksida L.M., Bussey T.J., Holmes A. Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice. Front. Behav. Neurosci. 2009, 3:2.
9. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
10. Cowansage K.K., LeDoux J.E., Monfils M.H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol. 2010, 3:12-29.
11. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol. Neurobiol. 2006, 26:365-384.
12. Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 1998, 49:196-201.
13. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
14. Curley A.A., Arion D., Volk D.W., safu-Adjei J.K., Sampson A.R., Fish K.N., Lewis D.A. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 2011, 168:921-929.
15. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 2001, 24:43-49.
16. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J., Burket J.A., Weizman A. Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions. Isr. J. Psychiatry Relat. Sci. 2010, 47:17-26.
17. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr. Res. 2012, 46:1-11.
18. Geffen Y., Keefe R., Rabinowitz J., Anand R., Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J. Clin. Psychiatry 2012, 73:e1168-e1174.
19. Goff D.C., Herz L., Posever T., Shih V., Tsai G., Henderson D.C., Freudenreich O., Evins A.E., Yovel I., Zhang H., Schoenfeld D. A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005, 179:144-150.
20. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57:1061-1069.
21. Hammond J.C., McCullumsmith R.E., Funk A.J., Haroutunian V., Meador-Woodruff J.H. Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 2010, 35:2110-2119.
22. Hartling L., bou-Setta A.M., Dursun S., Mousavi S.S., Pasichnyk D., Newton A.S. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Annu. Intern. Med. 2012, 157:498-511.
23. Harvey R.J., Yee B.K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat. Rev. Drug Discov. 2013, 12:866-885.
24. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005, 25:372-383.
25. Herdon H.J., Godfrey F.M., Brown A.M., Coulton S., Evans J.R., Cairns W.J. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 2001, 41:88-96.
26. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1113-1123.
27. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
28. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17:31-108.
29. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 2004, 9(984-997).
30. Kalkman H.O., Loetscher E. GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic-theories of psychosis. J. Neural Transm. 2003, 110:803-812.
31. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999, 156:286-293.
32. Kasper S., Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003, 28(Suppl. 1):27-38.
33. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 2005, 10:808-819.
34. Lane H.Y., Lin C.H., Huang Y.J., Liao C.H., Chang Y.C., Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13:451-460.
35. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams D.L., Sur C., Kinney G.G. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 2006, 6:771-785.
36. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3:303-314.
37. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013, 14:7-23.
38. Poels, Kegeles, Kantrowitz, Slifstein, Javitt, Lieberman, bi-Dargham and Girgis, Imaging glutamate in schizophrenia: review of findings and implications for drug discovery, Mol. Psychiatry, in press.
39. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
40. Rung J.P., Carlsson A., Ryden M.K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:827-832.
41. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 2010, 4:56-73.
42. Seibt K.J., Piato A.L., da Luz O.R., Capiotti K.M., Vianna M.R., Bonan C.D. Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio). Behav. Brain Res. 2011, 224:135-139.
43. Seillier A., Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav. Brain Res. 2009, 204:410-415.
44. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
45. Snigdha S., Neill J.C., McLean S.L., Shemar G.K., Cruise L., Shahid M., Henry B. Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J. Mol. Neurosci. 2011, 43:337-345.
46. Timms A.E., Dorschner M.O., Wechsler J., Choi K.Y., Kirkwood R., Girirajan S., Baker C., Eichler E.E., Korvatska O., Roche K.W., Horwitz M.S., Tsuang D.W. Support for the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013, 70:582-590.
47. Umbricht, D., Yoo, K., Youssef, E., Dorflinger, E., Martin-Facklam, M., Bausch, A., Arrowsmith, R., Alberati, D., Marder, S.R., Santarelli, L., 2010. Glycine transporter type 1 (GLYT1) inhibitor RG1678: Positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: Conference Proceeding of the 49th Annual Meeting, ACNP, Miami Beach, FL. Neuropsychopharmacology, vol. 35, pp. S320-S321.
48. Walz C., Jungling K., Lessmann V., Gottmann K. Presynaptic plasticity in an immature neocortical network requires NMDA receptor activation and BDNF release. J. Neurophysiol. 2006, 96:3512-3516.
49. Wang C.Z., Johnson K.M. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J. Neurosci. Res. 2005, 81:284-292.
50. Worms P., Kan J.P., Wermuth C.G., Biziere K. Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study. Naunyn Schmiedebergs Arch. Pharmacol. 1986, 334:246-252.
51. Yin D.M., Chen Y.J., Sathyamurthy A., Xiong W.C., Mei L. Synaptic dysfunction in schizophrenia. Adv. Exp. Med. Biol. 2012, 970:493-516.